About

Deborah H. Telman served as Gilead's Executive Vice President, Corporate Affairs and General Counsel until December 5, 2025, when she ceased to serve in that role, with her employment terminating later that month under a severance agreement. She was a named executive officer for fiscal 2025 and received a pro-rated target annual bonus pursuant to the Gilead Sciences, Inc. Severance Plan.

Roles

Gilead Sciences, Inc.
Former Executive Vice President, Corporate Affairs and General Counsel · Current role
Present
Gilead Sciences, Inc.
Executive Vice President, Corporate Affairs and General Counsel · Ceased to serve on December 5, 2025.
—

Fixed Compensation

FY 2025
Salary
$977,334
ComponentAnnual base salary (FY2025)
All other compensation
$55,478
Perquisites and other personal benefits$28,994
Contributions to 401(k) plan$15,000
Insurance premiums$11,484
Total compensation
$5,004,669

Performance Compensation

Data from FY 2025

Stock awards

Stock awards
$3,071,792
FormPerformance shares (50% of target LTI) and restricted stock units (25% of target LTI)
Performance shares metricRelative Total Shareholder Return (TSR) and multi-year EPS growth, earned over three years
RSU vestingOver four years
Option awards
$900,065
FormStock options
Weight of target LTI25%

Also at Gilead Sciences, Inc.

Colleague
Daniel P. O'Day
Chairman and Chief Executive Officer
Colleague
Andrew D. Dickinson
Chief Financial Officer
Colleague
Johanna Mercier
Chief Commercial and Corporate Affairs Officer

Related

Company
Gilead Sciences, Inc.
Company hub
Deal
Gilead Sciences Cell Design Labs 2017
Deal page
Deal
Gilead Sciences Cymabay Therapeutics 2024
Deal page

See how VectorShift works for your firm

Request Demo